Amarin reported $3K in Interest Expense on Debt for its fiscal quarter ending in December of 2024.





Interest Expense On Debt Change Date
AbbVie USD 688M 58M Sep/2026
Alnylam Pharmaceuticals USD -84.37M 166.42M Sep/2026
Amarin USD 3K 5K Dec/2024
AstraZeneca USD 371M 31M Sep/2026
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
DBV Technologies USD 461K 323.71K Mar/2025
GlaxoSmithKline GBP 219M 98M Sep/2026
Halozyme Therapeutics USD 6.04M 457K Sep/2026
Heron Therapeutics USD 600K 100K Dec/2024
Ionis Pharmaceuticals USD 4M 14M Sep/2026
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Neurocrine Biosciences USD 300K 2.6M Sep/2026
Novartis USD 468M 6M Sep/2026